CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Nikita Singh
/ Categories: Trending, Markets

Cadila Healthcare completes USFDA inspection of API plant

Pharma major Cadila Healthcare announced that the USFDA has successfully completed the inspection of its API manufacturing facility at Dabhasa. Following the development, the stock of the company surged by over 3 per cent on the bourses. 
 
The company also secured the final nod from the USFDA for Valacyclovir tablets, Clomipramine Hydrochloride Capsules, Nifedipine Extended-Release Tablets and Clozapine Tablets USP among others in the month of December in 2017. The group has secured over 180 approvals and has filed over 310 ANDAs since the commencement of the filing process in the fiscal year 2003-04.       
 
The stock hit an intraday high of Rs. 450.55 per share and an intraday low of Rs. 433.40 per share on BSE on Friday. The stock had hit its 52-week high of Rs. 558 per share on June 12, 2017 and its 52-week low of Rs. 334.35 per share on January 31, 2017 on BSE, respectively. 
 
On Friday, the stock recorded a spurt in volume of more than 1.13 times against its average volume on BSE. At 1515 hours IST, the stock was trading at Rs. 441.90 per share, higher by 1.33 per cent, respectively. 
 
Zydus Cadila is aspiring to become a research-based pharmaceutical company by 2020. 

Previous Article ITC surges for third day in a row ahead of Q3 results
Next Article Healthcare Global spurts post increase in FPI investment cap
Print
3029 Rate this article:
4.0
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR